Despite Financial Turmoil, Biotechs Still Able to Secure Venture Capital in Q3 ‘08 | GenomeWeb
The recent upheaval in the credit and equity markets has had no apparent affect on the ability of growing biotechs to secure venture capital in the third quarter, while medical device investment is harder to glean, according to figures released by two trackers of VC market trends.
The reports also showed that the San Francisco Bay Area extended its dominance as the nation’s largest cluster for both biotech and medical devices during the period, both by dollars raised and numbers of deals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.